Annovis Strengthens Leadership Team With Appointment Of Mark Guerin As CFO

Annovis Bio, Inc., a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced the appointment of Mark Guerin, CPA, CMA, CFM, as its new Chief Financial Officer. His appointment comes at a significant point for the company as it advances buntanetap, its lead investigational therapy, which is currently showing strong potential in late-stage clinical development.

Mark Guerin brings with him broad experience in financial leadership within the biopharmaceutical sector. He joined Onconova Therapeutics in 2013, following the company’s IPO, to strengthen its financial reporting, forecasting, and internal controls. In 2016, he was named Chief Financial Officer and during his tenure, he oversaw a number of important financial transactions, including rights offerings, public offerings, registered direct offerings, and at-the-market offerings. In April 2024, Onconova merged with Trawsfynydd Therapeutics to form Traws Pharma, Inc., supported by investments from OrbiMed and Torrey Pines. 

This merger allowed the combined company to advance a broader portfolio of therapies in virology and oncology. Later that year, in December 2024, the company also completed an additional $20 million financing round, strengthening its pipeline development efforts. Prior to his work at Onconova, Guerin held several leadership positions across the biopharma industry. He worked as an interim senior finance and accounting executive, where he assisted private equity portfolio companies with integration activities following acquisitions. 

Mark Guerin, CFO at Annovis, stated, “I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies. I look forward to supporting the clinical success of buntanetap and to Annovis delivering a therapeutic solution for patients who need it most.”

He also served as Vice President of Finance and later Chief Financial Officer at Cardiokine, Inc., where he played a key role in filing the company’s New Drug Application and guiding it through a successful sale. Earlier in his career, he was Director of Financial Reporting and Internal Controls at Barrier Therapeutics, Inc., where he supported the company through both its initial public offering and a follow-on offering. Guerin began his career at Coopers & Lybrand in Philadelphia. He holds a bachelor’s degree in accounting from DeSales University and has earned professional certifications as a Certified Public Accountant (CPA), Certified Management Accountant (CMA), and Certified Financial Manager (CFM).